Journal
VISZERALMEDIZIN
Volume 31, Issue 4, Pages 259-264Publisher
KARGER
DOI: 10.1159/000435868
Keywords
Crohn's disease; Stenosis; Fibrosis
Categories
Funding
- Abbvie
- Ferring
- Falk
- MSD
- Merck
- Takeda
- Hospira
- Mundipharma
Ask authors/readers for more resources
Introduction: The present review serves to provide a concise overview of the current knowledge on therapeutic strategies with regard to fibrostenotic lesions in Crohn's disease. Methods: A literature search was performed focusing on the last 5 years, and current concepts of pathophysiology, epidemiology, and treatment have been summarized. Results: Fibrostenotic lesions in Crohn's disease are currently considered to be a consequence of the chronic inflammatory nature of the disease. Hence, therapeutic strategies are limited to the concept that early treatment of the inflammatory lesions can prevent structural changes, and to various endoscopic and surgical approaches. Direct targeting of the fibrostenotic lesion itself has not been the focus until now. This review will provide an overview of the pathophysiology and epidemiology of fibrostenotic lesions including current therapeutic approaches. Since research with regard to other organ systems and fibrosis is far more advanced, current strategies from available studies in these areas will be discussed. The results and the potential impact for Crohn's disease will be considered. Conclusion: The vision of these approaches is to reverse structural changes and restore normal function. (C) 2015 S. Karger GmbH, Freiburg
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available